For years, many Medicare Advantage organizations treated HCC risk adjustment as a volume exercise: capture more diagnoses, lift RAF scores, and increase reimbursement. That approach still looks attractive on paper, but in 2026 it’s increasingly unsustainable. CMS audit activity has intensified, CMS-HCC Version 28 has reshaped risk coefficients and mappings, and quality programs like HEDIS are more tightly linked to accurate documentation. The result: the question has shifted from “Was the diagnosis submitted?” to “Can the diagnosis survive scrutiny?”

The conversation around fraud in laboratory billing, especially in genetic and molecular diagnostics, is no longer theor...
read more
In today’s US healthcare market, laboratory revenue cycle management (lab RCM) is no longer just about clean billing – i...
read more
Artificial Intelligence (AI) is steadily reshaping digital pathology – but not through sudden disruption or autonomous d...
read more
Medicare clawbacks related to urinary tract infection (UTI) testing are no longer isolated compliance events. As we move...
read more
With telehealth now a mainstream mode of care, many pathology labs, clinical laboratories, and behavioral health provide...
read more
The 2025 Clinical Laboratory Fee Schedule (CLFS) update has given U.S. labs extra time to prepare for the upcoming Janua...
read more
Effective October 1, 2025, the American Medical Association (AMA) introduced 25 new Proprietary Laboratory Analyses (PLA...
read more
Running a pathology group or diagnostic laboratory is challenging enough – but revenue cycle challenges make it even har...
read more
If you’re a U.S. healthcare provider searching for medical billing and coding services, you’re not alone. Thousands of p...
read more